Extending Contingency Management's Benefits With Progressively Increasing Variable Interval Prize Reinforcement
NCT ID: NCT01184040
Last Updated: 2019-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
61 participants
INTERVENTIONAL
2010-05-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reinforcing Exercise in Substance Abusing Patients
NCT01204879
The Effect of a Contingency Management Intervention on Substance Use
NCT00252512
Group-Based Contingency Management for Substance Abuse Treatment - 1
NCT00249717
Substance Use and Fitness
NCT01305902
A SMART Design for Attendance-based Prize CM
NCT00840151
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
(A) Non-contingent control
Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
No interventions assigned to this group
VIP CM
Participants assigned to Increasing Variable Interval Prize (VIP) Reinforcement group will be scheduled for the same study visits as those in the Control group, but will also earn chances to win prizes if they have walked more than 10,000 steps in the past 4 days.
VIP CM
Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VIP CM
Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* currently not physically active
* Physically able and willing to walk 10,000 steps per day
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
UConn Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nancy M Petry, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
UConn Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UConn Heatlh Center
Farmington, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-249-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.